RISK-ADAPTED AND MRD-DRIVEN STRATEGY

Clinical trials for RISK-ADAPTED AND MRD-DRIVEN STRATEGY explained in plain language.

Never miss a new study

Get alerted when new RISK-ADAPTED AND MRD-DRIVEN STRATEGY trials appear

Sign up with your email to follow new studies for RISK-ADAPTED AND MRD-DRIVEN STRATEGY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug combo challenges chemo for leukemia treatment

Disease control Completed

This study tested whether a newer, chemotherapy-free combination of two targeted drugs (venetoclax and ibrutinib) could be as good as or better than the standard chemotherapy-based treatment (FCR) for patients with intermediate-risk chronic lymphocytic leukemia (CLL). It involved…

Matched conditions: RISK-ADAPTED AND MRD-DRIVEN STRATEGY

Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

RISK-ADAPTED AND MRD-DRIVEN STRATEGY

Get alerted when new RISK-ADAPTED AND MRD-DRIVEN STRATEGY trials appear

New drug combo challenges chemo for leukemia treatment